You are here

Prices & Quotes - UK Markets - Oxford Biomedica (OXB)

Risk Warning The value of investments can fall as well as rise and any income from them is not guaranteed and you may get back less than you invested. Past performance is not a guide to future performance.

Share Price:
Up 1,280.00p
Change Today:
12.00p
Market Cap:
1,056.64m
Sector:
Pharmaceuticals & Biotechnology

Oxford Biomedica partner delays Parkinson's disease treatment trial

By Iain Gilbert

Date: Friday 30 Oct 2020

LONDON (ShareCast) - (Sharecast News) - Gene and cell therapy group Oxford Biomedica said on Friday that partner Axovant Gene Therapies had pushed out the start date for its trial into a Parkinson's disease treatment.
Oxford stated patient-level data from Axovant Gene Therapies' second cohort study into SUNRISE-PD had demonstrated "consistent, clinically meaningful outcomes" and evidence of dose-response.

However, Oxford Biomedica said the development of a suspension-based manufacturing process would take longer than initially anticipated as a result of data and finishing issues.

Axovant now anticipates that a randomised, sham-controlled trial would likely be unable to enrol patients before the end of 2021.

In June 2018, Oxford Biomedica out-licensed OXB-102, later renamed AXO-Lenti-PD, to Axovant through an $842.5m worldwide licence agreement, with a three-year clinical supply agreement later being signed in July 2020.

As of 0845 GMT, Oxford shares were down 0.47% at 812.18p.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

OXB Market Data

Currency UK Pounds
Price 1,280.00p
Change Today 12.00p
52 Week High 1,328.00p
52 Week Low 701.00p
Volume 47,291
Shares Issued 82.55m
Market Cap 1,056.64m

Performance Indicators

Compare performance with the sector and the market.

Key
Vs Market
Vs Sector
Value
market
  1. half market star
  2. empty market
  3. empty market
  4. empty market
  5. empty market
sector
  1. half sector star
  2. empty sector
  3. empty sector
  4. empty sector
  5. empty sector
Price Trend
market
  1. full market star
  2. full market star
  3. full market star
  4. full market star
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. empty sector
  5. empty sector
Income
Not Available
Growth
market
  1. full market star
  2. full market star
  3. full market star
  4. half market star
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. empty sector
  5. empty sector
Price Chg 6m
market
  1. full market star
  2. full market star
  3. full market star
  4. half market star
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. empty sector
  5. empty sector
P/E
Not Available
PEG
market
  1. full market star
  2. full market star
  3. full market star
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. full sector star
  5. empty sector
Dividend Yield
Not Available
EPS Growth
Not Available
Operating Margin
market
  1. full market star
  2. half market star
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. half sector star
  4. empty sector
  5. empty sector

What The Brokers Say

Strong Buy 4
Buy 0
Neutral 2
Sell 0
Strong Sell 0
Total 6
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

OXB Dividends

No dividends found

Trades for 22-Jun-2021

Time Volume / Share Price
16:35 20,609 @ 1,280.00p
16:29 151 @ 1,278.00p
16:29 9 @ 1,278.00p
16:28 1 @ 1,276.00p
16:28 8 @ 1,278.00p

OXB Key Personnel

CEO John Dawson
CFO Stuart Paynter